Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis

Simple item page
dc.contributor.authorIbanez, Patricio
dc.contributor.authorSolis, Nancy
dc.contributor.authorPizarro, Margarita
dc.contributor.authorAguayo, Gloria
dc.contributor.authorDuarte, Ignacio
dc.contributor.authorMiquel, Juan Francisco
dc.contributor.authorAccatino, Luigi
dc.contributor.authorArrese, Marco
dc.date.accessioned2024-01-10T12:05:06Z
dc.date.available2024-01-10T12:05:06Z
dc.date.issued2007
dc.description.abstractBackground and aim: Nonalcoholic steatohepatitis (NASH) is a metabolic disorder of the liver that may evolve into fibrosis or cirrhosis. Recent studies have shown reduction of experimental liver fibrosis with the use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor antagonists. The aim of this study was to determine whether losartan can influence the early phase of fibrogenesis in an animal model of NASH.
dc.description.abstractMethods: To induce NASH, a choline-deficient diet (CDD) was given to Sprague-Dawley rats for 12 weeks. These animals were then compared with a control group receiving choline-supplemented diet (CSD) and a group fed a CDD plus losartan (10 mg/kg/day). Biochemical (serum levels of alanine aminotransferase and aspartate aminotransferase) and histological evaluation of fatty liver was performed by conventional techniques. Hydroxyproline content in liver tissue was assayed by spectrophotometry. In addition, mRNA levels of procollagen I and transforming growth factor (TGF)-beta were assessed by semiquantitative RT-PCR and stellate cell activation by alpha-actin immunofluorescence stain.
dc.description.abstractResults: After 12 weeks CDD induced a marked elevation of serum aminotranferases, a severe fatty liver infiltration with mild histological inflammation and fibrosis. These findings correlated with a significant increase in mRNA levels of both procollagen I and TGF-beta and significant increased liver hydroxyproline content. No differences were seen between rats receiving CDD alone and rats receiving CDD plus losartan with regard to the biochemical, morphological or molecular alterations induced by the CDD.
dc.description.abstractConclusions: Losartan does not seem to influence liver injury and fibrogenic events in the CDD model of NASH.
dc.fechaingreso.objetodigital2024-05-09
dc.format.extent6 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1111/j.1440-1746.2006.04700.x
dc.identifier.eissn1440-1746
dc.identifier.issn0815-9319
dc.identifier.pubmedidMEDLINE:17565640
dc.identifier.urihttps://doi.org/10.1111/j.1440-1746.2006.04700.x
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/75946
dc.identifier.wosidWOS:000247205600016
dc.information.autorucMedicina;Accatino L;S/I;99016
dc.information.autorucMedicina;Arrese M;S/I;76095
dc.information.autorucMedicina;Miquel J;S/I;72216
dc.issue.numero6
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final851
dc.pagina.inicio846
dc.publisherWILEY
dc.revistaJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
dc.rightsacceso restringido
dc.subjecthepatic fibrosis
dc.subjectlosartan
dc.subjectrenin-angiotensin system
dc.subjectsteatohepatitis
dc.subjecttransforming growth factor-beta
dc.subjectINDUCED PULMONARY-FIBROSIS
dc.subjectSTELLATE CELL ACTIVATION
dc.subjectPATHOGENESIS
dc.subjectCIRRHOSIS
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleEffect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis
dc.typeartículo
dc.volumen22
sipa.codpersvinculados99016
sipa.codpersvinculados76095
sipa.codpersvinculados72216
sipa.indexWOS
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis.pdf
Size:
3.44 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas